Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation: 2014-2019

Historic Accumulated Depreciation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Mar 2019 value amounting to $3.2 million.

  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation was N/A to $3.2 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2018, which is N/A change from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Accumulated Depreciation of $3.2 million as of Q1 2019, which was up 2.23% from $3.1 million recorded in Q4 2018.
  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation's 5-year high stood at $3.2 million during Q1 2019, with a 5-year trough of $600,000 in Q1 2015.
  • Moreover, its 2-year median value for Accumulated Depreciation was $3.1 million (2018), whereas its average is $3.1 million.
  • Data for Viridian Therapeutics, Inc.\DE's Accumulated Depreciation shows a peak YoY spiked of 33.73% (in 2015) over the last 5 years.
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation (Quarterly) stood at $739,000 in 2015, then rose by 27.31% to $881,000 in 2016, then reached $3.1 million in 2018, then reached $3.2 million in 2019.
  • Its last three reported values are $3.2 million in Q1 2019, $3.1 million for Q4 2018, and $881,000 during Q3 2016.